Menu Search
Equities

Stryker Corp

SYK:MCX

Stryker Corp

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. The Company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. Its products are sold in over 75 countries through Company-owned subsidiaries and branches, as well as through third-party dealers and distributors. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Its geographical segments include United States and International.

  • Revenue in USD (TTM)18.45bn
  • Net income in USD2.36bn
  • Incorporated1946
  • Employees51.00k
  • Location
    Stryker Corp2825 Airview BlvdKALAMAZOO 49002United StatesUSA
  • Phone+1 (269) 389-2600
  • Fax+1 (269) 385-1062
  • Websitehttps://www.stryker.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SYK:NYQ since
announced		Transaction
value
Cerus Endovascular IncAnnounced30 Sep 202230 Sep 2022Announced38.93%--
Data delayed at least 15 minutes, as of Mar 31 2023 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.